Simponi golimumab: Phase III data

The double-blind, international Phase III GO-FURTHER trial in 592 patients with active moderate to severe RA despite methotrexate treatment showed that 2 mg/kg IV Simponi given at weeks 0 and 4 and then every 8 weeks plus methotrexate met the primary endpoint of improving ACR20 response rate at week 14 vs. placebo plus methotrexate (59% vs.

Read the full 562 word article

How to gain access

Continue reading with a
two-week free trial.